依法韦仑,临床注释,变异和临床注释数据

id	等位基因	注释文本
155	*38	The CYP2B638 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2B638 allele in combination with a normal, decreased, no, or increased function allele may have increased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence toxicity of efavirenz.
154	*18	The CYP2B618 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2B618 allele in combination with a normal, decreased, no, or increased function allele may have increased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence toxicity of efavirenz.
153	*6	The CYP2B66 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B66 allele in combination with a normal, decreased, no, or increased function allele may have increased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence toxicity of efavirenz.
152	*2	The CYP2B62 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B62 allele in combination with another normal function allele may have decreased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of efavirenz.
151	*1	The CYP2B61 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B61 allele in combination with another normal function allele may have decreased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of efavirenz.

等位基因

注释文本

The CYP2B6*38 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2B6*38 allele in combination with a normal, decreased, no, or increased function allele may have increased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence toxicity of efavirenz.

154

*18

The CYP2B6*18 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2B6*18 allele in combination with a normal, decreased, no, or increased function allele may have increased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence toxicity of efavirenz.

153

The CYP2B6*6 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*6 allele in combination with a normal, decreased, no, or increased function allele may have increased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence toxicity of efavirenz.

152

The CYP2B6*2 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*2 allele in combination with another normal function allele may have decreased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of efavirenz.

151

The CYP2B6*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*1 allele in combination with another normal function allele may have decreased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of efavirenz.

id	证据的ID	总结
14703	1449156770	CYP2B6 6/6 is associated with increased likelihood of Toxic liver disease when treated with efavirenz in people with HIV as compared to CYP2B6 1/1.
14702	1449156721	CYP2B6 6 + 38 are associated with increased risk of Neurotoxicity Syndromes when treated with efavirenz as compared to CYP2B6 1/1.
14701	1448994067	CYP2B6 2/2 is associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV as compared to CYP2B6 1/1.
14700	1448993746	CYP2B6 6/6 is associated with increased risk of Long QT Syndrome when exposed to efavirenz in healthy individuals as compared to CYP2B6 1/1.
14699	1448993721	CYP2B6 6 is associated with increased risk of Toxic liver disease when treated with efavirenz in people with HIV as compared to CYP2B6 1/*1.
98	1184168515	CYP2B6 1 is not associated with Neurotoxicity Syndromes when treated with efavirenz in people with HIV as compared to CYP2B6 6.
97	827707534	CYP2B6 6/6 is associated with increased risk of drug-induced liver injury when treated with efavirenz in people with HIV as compared to CYP2B6 1/1.
96	1448993810	Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT.
95	1448636199	Genotype CC is associated with decreased likelihood of Drug Toxicity when treated with efavirenz in people with HIV Infections as compared to genotype TT.
94	1184473287	Genotype TT is associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections.
93	1183634232	Genotypes CC + CT are not associated with risk of Neurotoxicity Syndromes when treated with efavirenz in people with HIV Infections as compared to genotype TT.
92	1451289240	Allele C is not associated with increased likelihood of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to allele T.
91	PA166182846	Annotation of DPWG Guideline for efavirenz and CYP2B6
90	PA166182603	Annotation of CPIC Guideline for efavirenz and CYP2B6

证据的ID

总结

14703

1449156770

CYP2B6 *6/*6 is associated with increased likelihood of Toxic liver disease when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.

14702

1449156721

CYP2B6 *6 + *38 are associated with increased risk of Neurotoxicity Syndromes when treated with efavirenz as compared to CYP2B6 *1/*1.

14701

1448994067

CYP2B6 *2/*2 is associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.

14700